Dopaminergic antiparkinsonism agents aim to replace dopamine or prevent the degradation of dopamine.
Antiparkinson drugs that aim to replace dopamine in the central nervous system, either release dopamine or mimic the action of dopamine. Drugs that replace dopamine are generally given with peripherally acting dopa carboxylase inhibitors, to prevent the metabolism of levodopa to dopamine peripherally. Dopamine receptor agonists bind to dopamine receptors and mimic the action of dopamine.
Selective monoamine oxidase (MAO-B) inhibitors bind to the enzyme MAO-B and prevent dopamine from being broken down.
Antiparkinson agents are used to treat Parkinson's disease, which is a degenerative disorder of movement that occurs due to dopamine deficiency in the brain, particularly in the basal ganglia.
Subscribe to receive email notifications whenever new articles are published.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated June 1st, 2018), Cerner Multum™ (updated July 4th, 2018), Wolters Kluwer™ (updated June 4th, 2018) and others. To view content sources and attributions, please refer to our editorial policy.